

CURRICULUM VITAE

PERSONAL INFORMATION

Name
Address
Telephone
Fax
E-mail
Nationality
Date of birth

Alberto Zambon

(Office) Clinica Medica 1, Dipartimento di Medicina - Via Giustiniani 2, 35128 Padova, Italy

Italian

EXPERTISE

- Principal areas of expertise

MD: Internal Medicine, Endocrinology and Metabolism

PhD: Atherosclerosis, Lipid and lipoprotein metabolism, Lipid-lowering therapy and cardiovascular disease prevention, Atherosclerotic plaque pathophysiology

WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

PRESENT

University of Padova, Dept. of Medicine, Via Giustiniani 2, 35128 Padova - Italy
Physician – Academic Teaching Hospital

ASSOCIATE PROFESSOR OF MEDICINE

Inpatient clinic: Internal medicine ward; Outpatient: lipid clinic; Tutor for post-doctoral fellows in Endocrinology and Metabolism, Teaching activity: General Medicine and Endocrinology-Metabolism courses for Medical School Students

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

07/1999 – 06/2000

Division of Metabolism Endocrinology and Nutrition, University of Washington, 1959 N.E. Pacific St., Seattle, WA, USA

Physician – Academic Teaching Hospital

ACTING ASSISTANT PROFESSOR OF MEDICINE

Research on lipid metabolism; Teaching classes: Endo-Metabolism Course, Medical School

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

07/2000 – PRESENT

Division of Metabolism Endocrinology and Nutrition, University of Washington, 1959 N.E. Pacific St., Seattle, WA, USA

Physician – Academic Teaching Hospital

AFFILIATE ASSISTANT PROFESSOR OF MEDICINE

Research on lipid metabolism and atherosclerosis, and genetic forms of lipid disorders

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational

01/1982 – 07/1988

Medical School – University of Padova, Italy

Medicine and Surgery

- skills covered
- Title of qualification awarded
- Level in national classification (if appropriate)

Doctor in Medicine - M.D.

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

01/1991 – 03/1993 and 07/1995 – 11/1997

Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle, WA, USA, Mentor Prof. John D Brunzell

Post doctoral training in Endocrinology and Metabolism – Outpatient Lipid Clinic

Fellowship in Endocrinology and Metabolism

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

12/1993

School of Medicine, University of Padova, Italy

Clinical Endocrinology and Metabolism

National Board Certification in Endocrinology and Metabolism

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

06/1998

School of Medicine, University of Padova, Italy

Clinical and basic science research in the pathophysiology of aging and atherothrombotic process

Ph.D. in Gerontology

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

1999 – present

American Heart Association

Fellow

FAHA

- Dates (from – to)
- Name and type of organization providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

07/2004 – 08/2004 and 07/2006 – 08/2006

Children's Hospital Oakland Research Institute (CHORI), Lipid Laboratory, Oakland, CA, USA
Mentor Prof. RM Krauss

Lipoprotein metabolism – Advanced techniques to assess lipoprotein physico-chemical properties

Visiting Scientist

LANGUAGES

MOTHER TONGUE ITALIAN

OTHER LANGUAGES

ENGLISH
• Reading skills Excellent
• Writing skills Excellent
• Verbal skills Excellent

FRENCH
• Reading skills good
• Writing skills good
• Verbal skills good

ADDITIONAL INFORMATION

European Atherosclerosis Society – EAS - Related Activities

EAS Advanced Courses - Speaker

- EAS Course on Clinical Excellence in Lipidology and Prevention
Cesme-IZMIR, TURKEY, September 16-17, 2017
- EAS Advanced Course on Precision Medicine in Atherosclerosis
Paris, France, October 05-06, 2017.

Speaker at EAS Annual Meeting and on EAS Academy Online Presentation

- 84th EAS Innsbruck, Austria, May-June 2016, EBAC session on Gene therapy
Lipoprotein Lipase: Genetic severe hypertriglyceridemia
- 84th EAS Innsbruck, Austria, May-June 2016, EBAC session on Low HDL High
Triglyceride, Diabetic Dyslipidemia: Diabetic Dyslipidemia
- 85th EAS Congress Prague, Czech Republic, April 2017, Advanced Clinical Seminar:
How to treat diabetic dyslipidemia ,
- 85th EAS Congress Prague, Czech Republic, April 2017, EBAC Accredited Session:
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?
Atherogenic dyslipidemia (AD)
- 87th EAS Congress, Maastricht, The Netherlands May 2019, How can we improve
outcomes in our patients with CAD? What is the price to pay if we are not at goal?
- 87th EAS Congress, Maastricht, The Netherlands May 2019, TG Lowering and its
impact on CVD reduction: LDL-C is not the only "usual suspect"

Awards and Honors

- 1993 American Heart Association: Corresponding Fellow
- 1996 American Federation for Clinical Research and Western Society for Clinical Investigation: Award for outstanding postdoctoral research
- 1996 Selection for presentation at the Chairman's Session at the Joint Plenary Session of WSCI, WSAFCR, Carmel, CA, 02/15/1996
- 1996 American Heart Association: 1996-97 Fellowship Award
- 1997 American Society for Clinical Investigation: Award for the best abstract presented at the Annual Meeting of the American Federation for Medical Research - Western Section.
- 1997 Young Faculty Award of the Western Society for Clinical Investigation
- 1998 American Federation For Aging Research (AFAR): 1998-2001 Paul Beeson Physician Faculty Scholar
- 1999 Merck Young Investigators Conference on Lipid Research: Award for outstanding research contribution
- 2000 Young Investigator Award – American Federation for Medical Research.
- 2000 Dorothy Dillon Eweson Lecture on the Advances in Aging Research by AFAR
- 2000 Award for Outstanding Scientific Contributions in Medical Research – Scientific Committee, School of Medicine, University of Padua, Italy
- 2001 Award for Outstanding Scientific Contributions in Medical Research – Scientific Committee, School of Medicine, University of Padua, Italy
- 2002 AZTECC International Award for Training and Education for Cardiovascular Clinicians

Scientific Societies and Advisory Board Membership

- 1993- present Fellow and Gold Heart Member of the American Heart Association, Council on Arteriosclerosis, Thrombosis and Vascular Biology
- 1998- present Member of the Italian Society for the Study of Atherosclerosis (S.I.S.A.).
- 1998- present Member of the International Atherosclerosis Society (I.A.S.).
- 2003- 2012 Member of the International Advisory Board of the Meeting on “Drugs Affecting Lipid Metabolism”, DALM, Giovanni Lorenzini Foundation
- 2005- present Member of the Speakers Bureau of the International Atherosclerosis Society
- 2009 Member of the International Advisory Board – XV International Symposium on Atherosclerosis – Boston 14-18 June 2009
- 2011 Member of the International Advisory Board – XVI International Symposium on Atherosclerosis – Sydney 25-29 March 2012
- 2010- present Member of the European Atherosclerosis Society (E.A.S.)
- 2015 – present Council Member of the Fondazione Società Italiana Studio Arteriosclerosi
- 2016 - 2019 Chair of the International Atherosclerosis Society (IAS) Regional Federation of Europe
- 2016 - 2020 Member of the Executive Board of the International Atherosclerosis Society

Current Research Interests

Dr. Zambon is currently the Director of the lipoprotein core laboratory of the Centre for Atherosclerosis Prevention and Treatment of the Department of Medicine, University of Padua, Italy.

His research interests focus on:

1. Mechanisms of atherosclerotic plaque progression and regression and particularly on the genetic background leading to lipoprotein abnormalities responsible for the unstable atherosclerotic plaque;
2. Common pathophysiological links between lipoprotein abnormalities, specifically related to particle size and density, and endothelial dysfunction both as an early marker of atherosclerosis as well as a potential link between the atherosclerotic process and venous thromboembolism;
3. Lipid oxidation and brain small vessel disease (endothelial dysfunction at cerebral site) as potential clinically relevant background for the development of Alzheimer's Disease and predictor of cognitive decline.
4. Rare diseases of lipoprotein metabolism including HoFH and FCS with specific focus on homozygous LPL deficiency and targeted gene therapy (Glybera)

PUBLICATIONS

1. MANZATO E, ZAMBON S, ZAMBON A, CORTELLA A, CREPALDI G (1990).
Serum lipoprotein and apoprotein levels during ketanserin or metoprolol administration in hypertensive patients
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (47): 807-313
[ISSN 0011-393X]
2. MANZATO E, ZAMBON S, ZAMBON A, DIGITO M, CARRARO R, CREPALDI G, ENZI G (1992).
Lipoprotein sub-fraction levels and composition in obese subjects before and after gastroplasty.
INTERNATIONAL JOURNAL OF OBESITY (16): 573-8
[ISSN 0307-0565] PMID: 1326487
3. ZAMBON S, ZAMBON A, STABELLINI N, TARRONI G, GILLI P, CREPALDI G, MANZATO E (1993).
Lipoprotein abnormalities in hypertriglyceridaemic patients on long-term haemodialysis.
JOURNAL OF INTERNAL MEDICINE (234): 217-21
[ISSN 0954-6820] PMID: 8340745 IF= 6.051
4. ZAMBON A, HASHIMOTO SI, BRUNZELL JD (1993).
Analysis of techniques to obtain plasma for measurement of levels of free fatty acids.
JOURNAL OF LIPID RESEARCH (34): 1021-8
[ISSN 0022-2275] PMID: 8354949
5. ZAMBON A, TORRES A, BIJVOET S, GAGNE C, MOORJANI S, LUPIEN PJ, HAYDEN MR, BRUNZELL JD (1993).
Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency.
LANCET (341): 1119-21
[ISSN 0140-6736] PMID: 8097805 IF 59.102
6. ZAMBON A, AUSTIN MA, BROWN BG, HOKANSON JE, BRUNZELL JD (1993).
Effect of hepatic lipase on LDL in normal males and those with coronary artery disease.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (13):147-53
[ISSN 1079-5642] PMID: 8427851 IF 6.618
7. HOKANSON JE, AUSTIN MA, ZAMBON A, BRUNZELL JD (1993).
Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (13): 427-34
[ISSN 1079-5642] PMID: 8443147 IF 6.618
8. MANZATO E, ZAMBON S, ZAMBON A, CORTELLA A, SARTORE G, CREPALDI G (1993).
Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia..
CLIN CHIM ACTA (19):57-65
[ISSN 0009-8981] PMID: 8306464.

PUBLICATIONS

9. MANZATO E, ZAMBON A, LAPOLLA A, ZAMBON S, BRAGHETTO L, CREPALDI G, FEDELE D (1993).
Lipoprotein abnormalities in well-treated type II diabetic patients.
DIABETES CARE (16): 469-75
[ISSN 0149-5992] PMID: 8432219 IF 15.270
10. CAPELL WH, ZAMBON A, AUSTIN MA, BRUNZELL JD, HOKANSON JE (1996)
Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (16):1040-6
[ISSN 1079-5542] PMID: 8696944 IF 6.618
11. NEVIN DN, ZAMBON A, FURLONG CE, RICHTER RJ, HUMBERT R, HOKANSON JE, BRUNZELL JD.(1996)
Paraoxonase genotypes, lipoprotein lipase activity, and HDL
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (16):1243-9
[ISSN 1079-5542] PMID: 8857920 IF 6.618
12. ZAMBON A, SCHMIDT I, BEISIEGEL U, BRUNZELL JD (1997).
Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins.
JOURNAL OF LIPID RESEARCH (37): 2394-404
[ISSN 0022-2275] PMID: 8978491
13. ZAMBON A, DEEB SS, HOKANSON JE, BROWN BG, BRUNZELL JD (1998).
Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (18): 1723-9
[ISSN 1079-5642] PMID: 9812910 IF 6.618
14. ZAMBON A, HOKANSON JE (1998).
Lipoprotein classes and coronary disease regression.
CURRENT OPINION IN LIPIDOLOGY (9): 329-36
[ISSN 0957-9672] PMID: 9739489
15. BROWN BG, ZAMBON A, POULIN D, ROCHA A, MAHER VM, DAVIS JW, ALBERS JJ, BRUNZELL JD (1998).
Use of niacin, statins, and resins in patients with combined hyperlipidemia.
AMERICAN JOURNAL OF CARDIOLOGY (81): 52B-59B
[ISSN 0002-9149] PMID: 9526815
16. ZAMBON A, SARTORE G, PASSERA D, FRANCINI-PESENTI F, BASSI A, BASSO C, ZAMBON S, MANZATO E, CREPALDI G (1999).
Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women.
JOURNAL OF INTERNAL MEDICINE (246): 191-201
[ISSN 0954-6820] PMID: 10447788 IF 6.051
17. ZAMBON A, HOKANSON JE, BROWN BG, BRUNZELL JD (1999).
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
CIRCULATION (99): 1959-64
[ISSN 0009-7322] PMID: 10208998 IF 23.054

PUBLICATIONS

18. CARR MC, KIM KH, ZAMBON A, MITCHELL ES, WOODS NF, CASAZZA CP, PURNELL JQ, HOKANSON JE, BRUNZELL JD, SCHWARTZ RS (2000).
Changes in LDL density across the menopausal transition.
JOURNAL OF INVESTIGATIVE MEDICINE (48): 245-50
[ISSN 1081-5589] PMID: 10916282
19. CORRAO G, RUBBIATI L, BAGNARDI V, ZAMBON A, POIKOLAINEN K (2000).
Alcohol and coronary heart disease: a meta-analysis.
ADDICTION (95): 1505-23
[ISSN 0965-2140] PMID: 11070527
20. PURNELL JQ, ZAMBON A, KNOPP RH, PIZZUTI DJ, ACHARI R, LEONARD JM, LOCKE C, BRUNZELL JD (2000).
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.
AIDS (14): 51-7
[ISSN 0269-9370] PMID: 10714567
21. ZAMBON A, DEEB SS, BROWN BG, HOKANSON JE, BRUNZELL JD (2001).
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
CIRCULATION (103): 792-8
[ISSN 0009-7322] PMID: 11171785 IF 23.054
22. CARR MC, HOKANSON JE, ZAMBON A, DEEB SS, BARRETT PH, PURNELL JQ, BRUNZELL JD (2001).
The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity.
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (86): 2831-7
[ISSN 0021-972X] PMID: 11397895
23. ZAMBON A, BROWN BG, DEEB SS, BRUNZELL JD (2001).
Hepatic lipase as a focal point for the development and treatment of coronary artery disease.
JOURNAL OF INVESTIGATIVE MEDICINE (49): 112-8
[ISSN 1081-5589] PMID: 11217140
24. ZAMBON A, DEEB SS, BENSADOUN A, FOSTER KE, BRUNZELL JD (2001).
In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity.
JOURNAL OF LIPID RESEARCH (41): 2094-9
[ISSN 0022-2275] PMID: 11108744
25. FAGGIN E, ZAMBON A, PUATO M, DEEB SS, BERTOCCO S, SARTORE S, CREPALDI G, PESSINA AC, PAULETTO P (2002).
Association between the --514 C-->T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (40): 1059-66
[ISSN 0735-1097] PMID: 12354428 IF 18.639

PUBLICATIONS

26. RATAZZI M, PUATO M, FAGGIN E, BERTIPAGLIA B, ZAMBON A, PAULETTO P (2003).
C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?
JOURNAL OF HYPERTENSION (21): 1787-803
[ISSN 0263-6352] PMID: 14508181
27. ZAMBON A, BERTOCCO S, VITTURI N, POLENTARUTTI V, VIANELLO D, CREPALDI G (2003).
Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.
BIOCHEMICAL SOCIETY TRANSACTIONS (31): 1070-4
[ISSN 0300-5127] PMID: 14505482
28. ZAMBON A, DEEB SS, PAULETTO P, CREPALDI G, BRUNZELL JD (2003).
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.
CURRENT OPINION IN LIPIDOLOGY (14): 179-89
[ISSN 0957-9672] PMID: 12642787
29. DEEB SS, ZAMBON A, CARR MC, AYYOBI AF, BRUNZELL JD (2003).
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.
JOURNAL OF LIPID RESEARCH (44): 1279-86
[ISSN 0022-2275] PMID: 12639974
30. ZAMBON A, PAULETTO P, CREPALDI G (2005).
Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (22 Suppl 2): 20-23
[ISSN 0269-2813] PMID: 16225466
31. ZAMBON A, PUATO M, FAGGIN E, BERTOCCO S, VITTURI N, POLENTARUTTI V, DERIU GP, GREGO F, BERTIPAGLIA B, RATAZZI M, VIANELLO D, DEEB SS, PAULETTO P (2006).
Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: Impact of plaque composition and lipoprotein phenotype.
ATHEROSCLEROSIS (185): 121-6
[ISSN 0021-9150] PMID: 16005462
32. ZAMBON A, GERVOIS P, PAULETTO P, FRUCHART JC, STAELS B (2006).
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR- α Activators. Clinical and Experimental Evidence.
ARTERIOSCLER THROMB VASC BIOL 26(5):977-86 IF 6.618
[ISSN 1079-5642] PMID: 16424352
33. ZAMBON A, BROWN BG, HOKANSON JE, MOTULSKY AG, BRUNZELL JD (2006).
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
JOURNAL OF INTERNAL MEDICINE (259): 401-9
[ISSN 0954-6820] PMID: 16594908 IF 6.051
34. ZAMBON A, BROWN BG, DEEB SS, BRUNZELL JD (2006).
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
JOURNAL OF INTERNAL MEDICINE (259): 473-80
[ISSN 0954-6820] PMID: 16629853 IF 6.051

PUBLICATIONS

35. ZAMBON A, (2006).
Reducing cardiovascular risk in the diabetic patient: implications from the FIELD study.
DIABETES VASC DIS. RES. (3, SUPPL. 1): S16-S20. PMID: 17935056
36. CAGNING AC, ZAMBON A, ZARANTONELLO G, VIANELLO D, MARCHIORI M, MERCURIO D, BATTISTIN L (2007).
Serum lipoprotein phenotype and apo E genotype in Alzheimer's disease.
JOURNAL OF NEURAL TRANSMISSION 72:175-79,
[ISSN 0300-9564]
37. MAGGI S, ZAMBON A, NOALE M, GALLINA P, BIANCHI D, MARZARI C, LIMONGI F, CREPALDI G for the ILSA Working Group (2007).
Validity of the ATP III diagnostic criteria for the Metabolic Syndrome in an elderly Caucasian population. The Italian Longitudinal Study on Aging.
ATHEROSCLEROSIS 197(2):877-82
[ISSN 0021-9150] PMID: 16629853
38. ZAMBON A, (2007).
Type 2 diabetes patients: profiles, treatment and daily practice.
DIABETES VASC DIS. RES. (4, SUPPL. 2): S12-S16
PMID: 17935056
39. ZAMBON A, CUSI K. (2007)
The role of fenofibrate in clinical practice.
DIABETES VASC DIS. RES. (4 SUPPL 3):S15-20.
PMID: 17935056
40. ZAMBON A, MARCHIORI M, MANZATO E. (2008)
Obesità viscerale e dislipidemia: meccanismi fisiopatologici, implicazioni cliniche e terapia.
G ITAL CARDIOL, 9 (SUPPL 1-4):S29-S39. [ISSN 1827-8981]
41. STAELS B, MAES M, ZAMBON A (2008)
Fibrates and future PPAR-alpha agonists in the treatment of cardiovascular disease.
NAT CLIN PRACT CARDIOVASC MED 5(9):542-53
PMID: 18628776
42. POLI A, MARANGONI F, PAOLETTI R, MANNARINO E, LUPATTELLI G, NOTARBARTOLO A, AURELI P, BERNINI F, CICERO A, GADDI A, CATAPANO A, CRICELLI C, MARROCCO W, PORRINI M, STELLA R, VANOTTI A, VOLPE M, VOLPE R, CANNELLA C, PINTO A, DEL TOMA E, LA VECCHIA C, TAVANI A, MANZATO E, RICCARDI G, SIRTORI C, ZAMBON A; *Nutrition Foundation Of Italy.* (2008)
Non-pharmacological control of plasma cholesterol levels.
NUTR METAB CARDIOVASC DIS 2008 Feb;18(2):S1-16.
PMID: 18258418

PUBLICATIONS

43. FRUCHART J-C, SACKS F, HERMANS MP, ASSMANN G, BROWN WV, CHAPMAN MJ, DODSON PM, FIORETTO P, GINSBERG HN, KADOWAKI T, LABLANCHE J-M, MARX N, PLUTZKY J, ROSENSON RS, SMITH Jr SC, STAELS B, STOCK JK, SY R, WANNER C, ZAMBON A, ZIMMET P (2008)
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
DIABETES VASC DIS. RES. 5(4):319-335. PMID: 17935056
44. FRUCHART J-C, SACKS F, HERMANS MP, ASSMANN G, BROWN WV, CHAPMAN MJ, DODSON PM, FIORETTO P, GINSBERG HN, KADOWAKI T, LABLANCHE J-M, MARX N, PLUTZKY J, ROSENSON RS, SMITH Jr SC, STAELS B, STOCK JK, SY R, WANNER C, ZAMBON A, ZIMMET P (2008)
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
AM J CARDIOL. 17;102(10 SUPPL):1K-34K.
45. NORATA GD, RASELLI S, GRIGORE L , MAGGI FM, GARLASCHELLI K, VIANELLO D, BERTOCCO S, ZAMBON A, CATAPANO AL (2009)
Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells
ATHEROSCLEROSIS, 206(2):556-62.
46. WINNICKI M, PUATO M, SOMERS VK, ZAMBON A, MARCOVINA SM, RATTAZZI M, PHILLIPS BG, PAULETTO P (2010)
Leptin is Associated with the Size of the Apolipoprotein(a) Particle in African Tribal Populations Living on Fish or Vegetarian Diet.
ATHEROSCLEROSIS, 211(1):303-7
47. PUATO M, FAGGIN E, RATTAZZI M, ZAMBON A, CIPOLLONE F, GRAGO F, GANASSIN L, PLEBANI M, MEZZETTI A, PAULETTO P. (2010) **Atorvastatin Reduces Macrophage Accumulation in Atherosclerotic Plaques: A Comparison of a Nonstatin-Based Regimen in Patients Undergoing Carotid Endarterectomy.**
STROKE, 41(6):1163-68 IF 6.058
48. FRUCHART JC, SACKS FM, HERMANS MP, et al. (2010)
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R³i).
CURR MED RES OPIN, 26(8):1793-97
49. MAFFEIS C, PINELLI L, SURANO MG, FORNARI E, CORDIOLI S, VIANELLO D, CORRADI M, ZAMBON A (2012)
Pro-atherogenic postprandial profile: meal induced changes of lipoprotein sub-fractions and inflammation markers in obese boys.
NUTR METAB CARDIOVASC DIS. Mar 18. [Epub ahead of print]
50. CAGNIN A, POMPANIN S, MANFIOLI V, BRIANI C, ZAMBON A, SALADINI M, DAM M. (2011)
Gamma-hydroxybutyric acid - induced psychosis and seizures.
EPILEPSY & BEHAVIOR, 21:203-205.
51. BRUNZELL JD, ZAMBON A, DEEB SS (2012)
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype
BBA - Molecular and Cell Biology of Lipids, doi:10.1016/j.bbalip.2011.09.008

PUBLICATIONS

52. MIKHAILIDIS DP, ELISAF MS, RIZZO M, BERNEIS K, GRIFFIN B, ZAMBON A, ATHYROS V, DE GRAAF J, MÄRZ W, PARHOFER KG, RINI GB, SPINAS GA, TOMKIN GH, TSELEPIS AD, WIERZBICKI AS, WINKLER K, FLORENTIN M, POULOS EN (2011)
"European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
CURR VASC PHARMACOL, 9:533-571.
53. MIKHAILIDIS DP, ELISAF MS, RIZZO M, BERNEIS K, GRIFFIN B, ZAMBON A, ATHYROS V, DE GRAAF J, MÄRZ W, PARHOFER KG, RINI GB, SPINAS GA, TOMKIN GH, TSELEPIS AD, WIERZBICKI AS, WINKLER K, FLORENTIN M, POULOS EN (2011)
"European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary.
CURR VASC PHARMACOL, 9:531-532.
54. ZAMBON A. (2011)
Residual cardiovascular risk in secondary prevention
INTERN EMERG MED Oct 6, suppl. 1: 61-68 PMID: 22009614
55. PUATO M, ZAMBON A, FAGGIN E, RATTAZZI M, PAULETTO P. (2014)
Statin treatment and carotid plaque composition. Review of clinical studies
CURR VASC PHARMACOL E-PUB Oct 17 PMID: 23092412
56. CAGNIN A, LEON A, VIANELLO D, COLAVITO D, FAVARETTO S, ZARANTONELLO G, STECCA A, ERMANI M, ZAMBON A (2013)
LDL Density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease
J ALZHEIMERS 34(2):377-385 PMID: 23207490
57. TAGLIEPIETRA M, ZANUSSO G, FIORINI M, BONETTO N, ZARANTONELLO G, ZAMBON A, ERMANI M, MONACO S, MANARA R, CAGNIN A (2013)
Accuracy of diagnostic criteria for sporadic Creutzfeld-Jacob disease among rapidly progressive dementia
J ALZHEIMERS DIS 34(1): 231-238 PMID: 23207489
58. ZAMBON A, PUATO M, FAGGIN E, GREGO F, RATTAZZI M, PAULETTO P. (2013)
Lipoprotein remnants and dense LDL are associated with features of unstable atherosclerotic plaque: a flag for non-HDL-C
ATHEROSCLEROSIS 230:106-109
59. FRUCHART J-C, DAVIGNON J, HERMANS MP, AL-RUBEAN K, AMARENCO P, ASSMANN G, BARTER P, BETTERIDGE J, BRUKERT E, CUEVAS A, FARNIER M, FERRANINI E, FIORETTO P, GENEST J, GINSBERG HN, ZAMBON A ZHU J, ZIMMETH (2014)
Residual macrovascular risk in 2013: What have we learned?
CARDIOVASCULAR DIABETOLOGY Jan 24;13(1):26
60. ZAMBON A, ZHAO X-Q, BROWN BG, BRUNZELL JD (2014)
Niacin combination therapy, lipoproteins and cardiovascular disease
AM J CARDIOLOGY May 1;113(9):1494-8. PMID: 24641964
61. ZAMBON A, (2015)
The new ACC/AHA guidelines on the treatment of dyslipidemia: cons.
INTERN EMERG ,ED 10(2): 119-122 PMID: 25502590

PUBLICATIONS

62. AGUIAR C, ALEGRIA E, BONADONNA RC, CATAPANO AL, COSENTINO F, ELISAF M, FARNIER M, FERRIÈRES J, FILARDI PP, HANCU N, KAYIKCIOGLU M, MELLO E SILVA A, MILLAN J, REINER Ž, TOKGOZOGLU L, VALENSI P, VIIGIMAA M, VRABLIK M, ZAMBON A, ZAMORANO JL, FERRARI R., (2015)
A review of the evidence of reducing macrovascular risk in patients with atherogenic dyslipidemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
ATHEROSCLER SUPPL Sept 2015;19:1-12 doi: 10.1016/S1567-5688(15)30001-5. PMID:26315511
63. VITTURI N, SOATTIN M, De STEFANO F, VIANELLO D, ZAMBON A, PLEBANI M, BUSETTO L (2015)
Ultrasound, anthropometry and bioimpedance: a comparison in predisting fat deposition in non-alcoholic fatty liver disease.
EAT WEIGHT DISORD 20(2):241-247. PMID:25129033.
64. ARCA M, AVERNA M, CASULA M, CATAPANO AL, FELLIN R, ANGELICO F, AROSIO E, BERNINI F, CALANDRA S, CIPOLLONE F, CORSINI A, MEROTTA G, MUNTONI S, POLI A, SOLINI A, VAUDO G, ZAMBON A (2016)
Nuove terapie ipolipemizzanti per i pazienti con ipercolesterolemia familiare: Position paper della Società Italiana per lo studio della Arteriosclerosi
GIORNALE ITALIANO DELL'ARTERIOSCLEROSI 7(1):45-65.
65. FERRARI R, AGUIAR C, ALEGRIA E, BANADONNA RC, COSENTINO F, ELISAF M, FARNIER M, FERRIERES J, PERRONE FILARDI P, HANCU N, KAYIKCIOGLU M, MELLO E SILVA A, MILLAN J, REINER Z, TOKGOZOGLU L, VALENSI P, VIIGIMAA M, VRABLIK M, ZAMBON A, ZAMORANO JL, CATAPANO AL (2016)
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidemia.
EUR HEART J SUPPL 18:2-12 The Heart of the Matter doi:10.1093/eurheartj/suw009
66. ZAMBON A (2016)
Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies.
G ITAL CARDIOL (Rome). Apr;17(4):22-30. doi:10.1714/2254.24280 PMID:27312020.
67. CIMMINIELLO C, ZAMBON A, POLO FRIZ H (2016)
Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options.
G ITAL CARDIOL (Rome). Apr;17(4)6-13. doi: 10.1714/2254.24276 PMID:27312018
68. FIORETTO P, ZAMBON A, ROSSATO M, BUSETTO L, VETOR R (2016)
SHL2 Inhibitors and Diabetic Kidney. IF 15.270
DIABETES CARE (Suppl. 2):S165-S171. doi: 10.2337/dcS15-3006 PMID:27440829
69. ZAMBON A, (2017)
Reducing cholesterol levels to decrease cardiovascular events: The role of new proprotein convertase subtilisin/kexin type 9 inhibitors.
J CARDIOVASC MED. 2017, 18 (suppl 1):e184–e186 PMID:27841824
70. BERTO P, BILATO C, BONORA E, DeCONTO U, GRAZIANI MS, PAULETTO P, VETTOR R, ZAMBON A (2017)
Il rischio cardiovascolare e la concentrazione plasmatica del colesterolo LDL: il ruolo dei Servizi Sanitari Regionali.
GRHTA 2017, 4(1):e44-e46 doi: 10.5301/grhta.5000252

71. COLIVICCHI F, ZAMBON A (2017)
The FOURIER study
 G ITAL CARDIOL (Rome). Jul-Aug;18(7):533-540. doi: 10.1714/2729.27819.
 PMID:8714995
72. AVERNA M, CEFALÙ AB, CASULA M, NOTO D, ARCA M, BERTOLINI S, CALANDRA S, CATAPANO AL, TARUGI P; LIPIGEN GROUP (2017)
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).
 ATHEROSCLER SUPPL. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosis.2017.07.001. PMID: 28965615
73. PIRILLO A, GARLASCHELLI K, ARCA M, AVERNA M, BERTOLINI S, CALANDRA S, TARUGI P, CATAPANO AL; LIPIGEN GROUP (2017)
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
 ATHEROSCLER SUPPL. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosis.2017.07.002. PMID: 28965616
74. BILATO C, ANSELMINI M, CEMIN R, CITRONI N, RONCON L, ZAMBON A, ZAMBON S, ZENTI MG. (2017)
A practical tool for easier compilation of AIFA (Italian Medicines Agency) web-based registry for PCSK9 inhibitor prescription
 G ITAL CARDIOL (ROME). 2017 Nov;18(11):805-807. doi: 10.1714/2803.28370.
75. D'ERASMO L, MINICOCCI I, NICOLUCCI A, PINTUS P, ROETERS VAN LENNEP JE, MASANA L, MATA P, SÁNCHEZ-HERNÁNDEZ RM, PRIETO-MATOS P, REAL JT, ASCASO JF, LAFUENTE EE, POCOVI M, FUENTES FJ, MUNTONI S, BERTOLINI S, SIRTORI C, CALABRESI L, PAVANELLO C, AVERNA M, CEFALU AB, NOTO D, PACIFICO AA, PES GM, HARADA-SHIBA M, MANZATO E, ZAMBON S, ZAMBON A, VOGT A, SCARDAPANE M, SJOJKE B, FELLIN R, ARCA M. (2018)
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. IF 18.639
 J AM COLL CARDIOL. 2018 Jan 23;71(3):279-288. doi: 10.1016/j.jacc.2017.11.028.
76. NEELAND IJ, ROSS R, DESPRÉS J-P, MATSUZAWA Y, YAMASHITA S, SHAI I, SEIDELL J, MAGNI P, SANTOS RD, ARSENAULT B, CUEVAS A, HU FC, GRIFFIN B, ZAMBON A, BARTER P, FRUCHART J-C, ECKEL RH (2019)
Visceral and Ectopic Fat, Atherosclerosis, and Cardiometabolic Disease: A Joint Position of the International Atherosclerosis Society and International Chair on Cardiometabolic Risk Working Group on Visceral Obesity
 THE LANCET DIABETES & ENDOCRINOLOGY 2019 Sep;7(9):715-725. doi: 10.1016/S2213-8587(19)30084-1 IF 24.540
77. FRUCHART J-C, SANTOS RD, AGUILAR C, AIKAWA M, AL RASADI K, AMARENCO P, BARTER PJ, CESKA R, CORSINI A, DESPRES J-P, DURIEZ P, ECKEL RH, EZHOV MV, FARNIER M, GINSBERG HN, HERMANS MP, ISHIBASHI S, KARPE F, KODAMA T, KOENIG W, KREMPF M, LIM S, LORENZATTI AJ,....YOKOTE K, ZAMBON A, LIBBY P (2019)
The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα) Paradigm: Conceptual Framework and Therapeutic Potential - A Consensus Statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
 CARDIOVASCULAR DIABETOLOGY 2019 Jun 4;18(1):71 doi:10.1186/s12933-019-0864-7. PMID: 31164165

78. FRUCHART J-C, SANTOS RD, YAMASHITA S, LIBBY P et al. (2019)
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?; International Atherosclerosis Society/R3i Foundation Consensus Panel.
 DIABETES METAB SYNDR. 2019 Jul - Aug;13(4):2723-2725. doi:
 10.1016/j.dsx.2019.05.034. PMID:31405699
79. ROSS R, NEELAND I, YAMASHITA S, SHAI I, SEIDELL J, MAGNI P, DOS SANTOS R, ARSENAULT B, CUEVAS A, HU F, GRIFFIN B, ZAMBON A, BARTER P, FRUCHART J-C, ECKEL R, MATSUZAWA Y, AND DESPRÉS J-P. (2020)
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity
 NATURE REVIEWS ENDOCRINOLOGY 2020 Mar; 16(3):177-189. doi:
 10.1038/s41574-019-0310-7. **IF 24.646**
80. LETTINO M, ZAMBON A, MUSUMECI G, ARCA M, BILATO C, BRUNETTI ND, CALABRÒ P, CASU G, CHIARELLA F, FAGGIANO P, FERLINI M, GUARDIGLI G, IMBALZANO E, INDOLFI C, MARCUCCI R, MENOZZI A, MUREDDU GF, FILARDI PP, PIRRO M, PISCIOTTA L, SCHERILLO M, SUPPRESSA P, UGUCCIONI M, VARBELLA F, GENTILE L, RAPEZZI C, AVERNA M. (2020)
Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts
 G ITAL CARDIOL (Rome). 2020 Apr;21(4 Suppl 1):3S-21S. doi: 10.1714/3331.33006. Italian.
81. ZAMBON A (2020)
Non High-Density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidemia.
 DIABETES MELLITUS 2020, 23(1):65-71. doi:10.14341/DM10351
82. BARONI MG, MASULLI M, RUSSO G, SARTORE G, ZAMBON A, ZAMBON S (2020)
Consensus on the use of anti-PCSK9 antibodies in the management of lipid control of patients with diabetes mellitus.
 GIORNALE ITALIANO DELL'ARTERIOSCLEROSI 2020; 11 (1): 5-29
83. CASULA M, OLMASTRONI E, GAZZOTTI M, GALIMBERTI F, ZAMBON A, CATAPANO AL (2020)
Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage & baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials
 PHARMACOLOGICAL RESEARCH 2020 Oct; 160 Oct; 160:105060.
 doi: 10.1016/j.phrs.2020.105060; PMID: 32634581
84. WATTS G, CATAPANO AL, MASANA L, ZAMBON A, PIRILLO A, TOKGÖZOĞLU L (2020)
Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
 ATHEROSCLER SUPPL. 2020 Dec;42:e30-e34.
 doi:0.1016/j.atherosclerosissup.2021.01.006.PMID: 33589221
85. ZAMBON A, PIRILLO A, ZAMBON S, NORATA GD, CATAPANO AL (2020)
Omega n-3 supplementation: exploring the cardiovascular benefits beyond lipoprotein reductio
n
 CURR ATHEROSCL REPORT 2020 Oct 3;22(12):74. doi: 10.1007/s11883-020-00893-1.PMID: 33009961

86. CASULA M, GAZZOTTI M, BONAIFI F, OIMASTRONI E, ARCA M, AVERNA M, ZAMBON A, CATAPANO AL, ON BEHALF OF THE PROSISA STUDY GROUP (2021)
Reported Muscle Symptoms During Statin Treatment Among Italian Dyslipidemic Patients In The Real-Life Setting: The Prosisa Study
J INTERN MED 2021 Jul;290(1):116-128. doi: 10.1111/joim.13219.PMID: 33259671
87. CICERO AFG, FOGACCI F, ZAMBON A (2021)
Red yeast rice for Hypercholesterolemia.
J AM COLL CARDIOL 2021, Feb 9;77(5):620-628
88. AVERNA M, BANACH M, BRUCKERT E, DREXEL H, FARNIER M, GAITA D, MAGNI P, MÄRZ W, MASANA L, MELLO E SILVA A, REINER Z, ROS E, VRABLIK M, ZAMBON A, ZAMORANO JL, STOCK JK, TOKGÖZOĞLU LS, CATAPANO AL. (2021)
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.
ATHEROSCLEROSIS. 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039. Epub 2021 Apr 13.PMID: 33892925
89. ZAMBON A, MELLO E SILVA, FARBIER M. (2021)
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?
EUR HEART J CARDIOVASC PHARMACOTHER. 2021 Sep 21;7(5):435-441. doi: 10.1093/ehjcvp/pvaa123.PMID: 33119073
90. BONORA BM, ALBIERO M, MORIERI ML, CAPPELLARI R, AMENDOLAGINE FI, MAZZUCATO Z, ZAMBON A, IORI E, AVOGARO A, FADINI GP.(2021)
Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomized, placebo-controlled trial.
DIABETOLOGIA 2021 Oct;64(10):2334-2344. doi: 10.1007/s00125-021-05532-1. Epub 2021 Aug 9.PMID: 34368894
91. LUPO MG, ARCIDIACONO D, ZARAMELLA A, FIANI F, CALABRO P, CEFALU' AB, AVERNA M, D'ERASMO L, ARCA M, DE MARTIN S, ZAMBON A, FERRI N. (2021)
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile.
ATHEROSCLEROSIS PLUS, doi:10.1016/j.athplu.2021.05.001. pp.1-3 - ISBN:ISSN: 2667-0895.
92. CANCLINI L, MALVANDI AM, UBOLDI P, JABNATI N, GRIGORE L, ZAMBON A, BARAGETTI A, CATAPANO AL. ZAMBON A, PIRILLO A, ZAMBON S, NORATA GD, CATAPANO AL (2021)
The association of proprotein convertase subtilisin-kexin type 9 to plasma lipoproteins: an evaluation of different methods.
METABOLITES 2021, 11, 861. <https://doi.org/10.3390/metabo11120861>
93. OLMASTRONI E, MOLARI G, DE BENI N, COLPANI O, GALIMBERTI F, GAZZOTTI M, ZAMBON A, CATAPANO AL, CASULA M (2021)
Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies
EUR J PREV CARDIOL. 2021 Dec 6;zwab208. doi: 10.1093/eurjpc/zwab208. Online ahead of print,.PMID: 34871380
94. NAVARESE EP, GRZELAKOWSKA K, MANGINI F, KUBICA J, BANACH M, BENN M, BINDER CJ, BORÉN J, CATAPANO A, KRONENBERG F, MALLAT Z, MOULIN P, ÖÖRNI K, RAY KK, ROETERS VAN LENNEP JE, ROMEO S, TOKGOZOGLU L, VON

- ECKARDSTEIN A, ZAMBON A, RAGGI P (2022)
The spoils of war and the long-term spoiling of health conditions of entire nations.
ATHEROSCLEROSIS, ISSN: 0021-9150, doi: 10.1016/j.atherosclerosis.2022.05.012
95. ZAMBON A, AVERNA M., D'ERASMO L., ARCA M., CATAPANO A. (2022).
New and Emerging Therapies for Dyslipidemia.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, ISSN: 0889-8529, doi: 10.1016/j.ecl.2022.02.004
96. PEDERIVA C, SCICALI R, TOSCANO A, VIGNA GB, ZAMBON A, CATAPANO AL, CASULA M, GALIMBERTI F, GAZZOTTI M, OLMASTRONI E, ZAMPOLERI V (2022).
Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
ATHEROSCLEROSIS, vol. 349, p. 233-239, ISSN: 0021-9150, doi: 10.1016/j.atherosclerosis.2022.04.021
97. ADORNI MP, BIOLO M, ZIMETTI F, PALUMBO M, RONDA N, SCARINZI P, SIMIONI P, LUPO MG, FERRI N, PREVIATO L, BERNINI F, ZAMBON A (2022).
HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 23, ISSN: 1422-0067, doi: 10.3390/ijms23158255.
98. CEFALÙ AB, D'ERASMO L, IANNUZZO G, NOTO D, GIAMMANCO A, MONTALI A, ZAMBON A, FORTE F, SUPPRESSA P, GIANNINI S, BARBAGALLO CM, GANCI A, NARDI E, VERNUCCIO F, CALDARELLA R, CIACCIO M, ARCA M, AVERNA M (2022).
Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
ATHEROSCLEROSIS, vol. 358, ISSN: 0021-9150, doi: 10.1016/j.atherosclerosis.2022.08.017.
99. CICERO AFG, FOGACCI F, ZAMBON A, TOTTH PP, BORGHI C (2022).
Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies.
AMERICAN HEART JOURNAL PLUS, vol. 13, ISSN: 2666-6022, doi: 10.1016/j.ahjo.2022.100127
100. CEFALÙ AB, GARBELOTTO R, MOMBELLI G, PIRRO M, RUBBA P, ARCA M, BORGHI C, BONOMO K, GONNELLI S, MASSARONI K, TIRONE G, AVERNA M, ANGELICO F, CIPOLLONE F, CORGHI E, FAGGIANO P, GRECO GC, LUCCHI L, SABBA T, SARZANI C, TERROSU RP, ZAMBON A (2022).
A subgroup analysis of the ODYSSEY APPRISE study: safety and efficacy of alirocumab in the Italian cohort.
NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, ISSN: 0939-4753, doi: 10.1016/j.numecd.2022.07.020
101. ARCA M, AVERNA M, BORGHI C, LETTINO M, PERRONE FILARDI P, ALBERTI A, BILATO C, CALABRÒ P, CARUBBI F, CICCONE MM, CIPOLLONE F, CITRONI N, DE LUCA L, GIACCARI A, IANNUZZO G, MALOBERTI A, MARCUCCI R, PIGNATELLI SPINAZZOLA P, PIRRO M, PISCIOTTA L, SARULLO F, SCIACQUA A, SUPPRESSA P, VARBELLA F, WERBA JP, ZAMBON A (2023).
How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy.
GIORNALE ITALIANO DI CARDIOLOGIA, vol. 24, p. 770-780, ISSN: 1972-6481, doi: 10.1714/4100.40977
102. CASULA M, GAZZOTTI M, CAPRA ME, OLMASTRONI E, GALIMBERTI F, CATAPANO AL, PEDERIVA C, ZAMBON A (2023).
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study. ATHEROSCLEROSIS, p. 1-7, ISSN: 0021-9150, doi: 10.1016/j.atherosclerosis.2023.117231

103. RAJA V, AGUIAR C, ALSAYED N, CHIBBER YS, ELBADAWI H, EZHOV M, HERMANS MP, PANDEY RC, RAY KK, TOKGÖZOGLU L, ZAMBON A, BERROU J-P, FARNIER M (2023).
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. ATHEROSCLEROSIS, p. 1-32, ISSN: 0021-9150, doi: 10.1016/j.atherosclerosis.2023.117312.
104. BILATO C, ZAMBON A, PISCIOTTA L, CITRONI N, CARUBBI F, ZAMBON S, ZENTI MG, VINCI P, BIOLO G, BONOMO K, EGALINI F, PASSARO A, NASCIBENI F, NEGRI E, D'ADDATO S, AVERNA M, ARCA M, OLIVA F, COLIVICCHI F, CATAPANO A (2023). **Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion.** GIORNALE ITALIANO DI CARDIOLOGIA, vol. 24, p. 5-10, ISSN: 1972-6481, doi: 10.1714/3934.39174
105. ARCA M, CELANT S, OLIMPIERI PP, COLATRELLA A, TOMASSINI L, D'ERASMO L, AVERNA M, ZAMBON A, CATAPANO AL, RUSSO P (2023).
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients with Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE, vol. 12, p. 1-14, ISSN: 2047-9980, doi: 10.1161/JAHA.122.026550
106. CHAIT A, ECKEL RH, VRABLIK M, ZAMBON A (2023)
Lipid-lowering in diabetes: An update. ATHEROSCLEROSIS. 2023 Oct 6:117313. doi: 10.1016/j.atherosclerosis.2023.117313
107. EUROPEAN ATHEROSCLEROSIS SOCIETY FAMILIAL HYPERCHOLESTEROLAEMIA STUDIES COLLABORATION (2024)
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. LANCET. 2024 Jan 6;403(10421):55-66. doi: 10.1016/S0140-6736(23)01842-1. Epub 2023 Dec 12.

BOOK CHAPTERS

1. MANZATO E, ZAMBON S, ZAMBON A., CREPALDI G. *Dietary and drug treatment of dyslipidemias*
In: **ADVANCES IN VASCULAR PATHOLOGY** STRANO A, NOVO S.
Elsevier Science Publishers B.V. (1989) Vol. , pp. 1389-1394.
2. ZAMBON A., BRUNZELL J.D. *THE LIPOPROTEIN METABOLISM IN THE PLURIMETABOLIC SYNDROME*
In: **DIABETES, OBESITY AND HYPERLIPIDEMIA: THE PLURIMETABOLIC SYNDROME** CREPALDI G., TIENGO A., MANZATO E.
ELSEVIER SCIENCE PUBLISHER B.V. (1993) Vol. 1039, pp. 197-200.
3. BRUNZELL J.D., AUSTIN M.A., DEEB S.S., HOKANSON J.E., JARVIK J.P., NEVIN D.N., WIJSMAN E., ZAMBON A., MOTULSKY A.G. *FAMILIAL COMBINED HYPERLIPIDEMIA AND GENETIC RISK FOR ATHEROSCLEROSIS*
In: **ATHEROSCLEROSIS X** WOODFORD F.P., DAVIGNON J., SNIDERMAN A.
ELSEVIER SCIENCE PUBLISHER B.V. (1995) Vol. , pp. 624-627.
4. ZAMBON A., BRUNZELL J.D *FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA*
In: **HANDBUCH DER FETTSTOFFWECHSELSTORUNGEN** SCHWANDT P., RICHTER W.O., PARHOFER K.
SCHATTAUER (2001) Vol. , pp. 104-114.
5. CREPALDI G., ZAMBON A. *La Sindrome Plurimetabolica: storia ed attualità*
In: **4° Rapporto sull'Obesità in Italia** ISTITUTO AUXOLOGICO ITALIANO FRANCO ANGELI (2002) Vol. , pp. 5-28.
6. ZAMBON A., CREPALDI G *The Plurimetabolic Syndrome: qualitative lipoprotein abnormalities and atherosclerosis*
In: **The metabolic Syndrome: diabetes , obesity, hyperlipidemia and hypertension** CREPALDI G, TIENGO A, AVOGARO A.
Elsevier (2003) Vol. 1253, pp. 223-228.
7. VITTURI N, ZAMBON A., POLENTARUTTI V, BERTOCCO S, VIANELLO D, PAULETTO P, CREPALDI G *Dyslipidemia of the Plurimetabolic Syndrome and risk of cerebrovascular events*
In: **The metabolic Syndrome: diabetes, obesity, hyperlipidemia and hypertension** CREPALDI G, TIENGO A, AVOGARO A
ELSEVIER (2003) Vol. 1253, pp. 209-215.
8. ZAMBON A *Insulino-resistenza e Dislipidemia*
In: **INSULINO-RESISTENZA E SINDROME METABOLICA** Del Prato S
Primula Editrice (2005) Vol. , pp. 20-36.
9. PARHOFER K., ZAMBON A., BRUNZELL J.D *FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA*
In: **HANDBUCH DER FETTSTOFFWECHSELSTORUNGEN: dyslipoproteinämien und atherosklerose: diagnostik, therapie und prävention** (3rd Edition) SCHWANDT P., PARHOFER K.
SCHATTAUER (2007) Vol. , pp. 146-155.

Padova, 16 Luglio 2024

